A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot-Marie-Tooth type 1A.
CMT1A
Charcot–Marie–Tooth
Neuromuscular disorder
Overall Neuropathy Limitations Scale
PMP22
PXT3003
Randomized controlled trial
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
16 10 2021
16 10 2021
Historique:
received:
28
04
2021
accepted:
19
09
2021
entrez:
17
10
2021
pubmed:
18
10
2021
medline:
3
11
2021
Statut:
epublish
Résumé
Charcot-Marie-Tooth disease type 1A (CMT1A) is a rare, orphan, hereditary neuromuscular disorder with no cure and for which only symptomatic treatment is currently available. A previous phase 2 trial has shown preliminary evidence of efficacy for PXT3003 in treating CMT1A. This phase 3, international, randomized, double-blind, placebo-controlled study further investigated the efficacy and safety of high- or low-dose PXT3003 (baclofen/naltrexone/D-sorbitol [mg]: 6/0.70/210 or 3/0.35/105) in treating subjects with mild to moderate CMT1A. In this study, 323 subjects with mild-to-moderate CMT1A were randomly assigned in a 1:1:1 ratio to receive 5 mL of high- or low-dose PXT3003, or placebo, orally twice daily for up to 15 months. Efficacy was assessed using the change in Overall Neuropathy Limitations Scale total score from baseline to months 12 and 15 (primary endpoint). Secondary endpoints included the 10-m walk test and other assessments. The high-dose group was discontinued early due to unexpected crystal formation in the high-dose formulation, which resulted in an unanticipated high discontinuation rate, overall and especially in the high-dose group. The statistical analysis plan was adapted to account for the large amount of missing data before database lock, and a modified full analysis set was used in the main analyses. Two sensitivity analyses were performed to check the interpretation based on the use of the modified full analysis set. High-dose PXT3003 demonstrated significant improvement in the Overall Neuropathy Limitations Scale total score vs placebo (mean difference: - 0.37 points; 97.5% CI [- 0.68 to - 0.06]; p = 0.008), and consistent treatment effects were shown in the sensitivity analyses. Both PXT3003 doses were safe and well-tolerated. The high-dose group demonstrated a statistically significant improvement in the primary endpoint and a good safety profile. Overall, high-dose PXT3003 is a promising treatment option for patients with Charcot-Marie-Tooth disease type 1A.
Sections du résumé
BACKGROUND
Charcot-Marie-Tooth disease type 1A (CMT1A) is a rare, orphan, hereditary neuromuscular disorder with no cure and for which only symptomatic treatment is currently available. A previous phase 2 trial has shown preliminary evidence of efficacy for PXT3003 in treating CMT1A. This phase 3, international, randomized, double-blind, placebo-controlled study further investigated the efficacy and safety of high- or low-dose PXT3003 (baclofen/naltrexone/D-sorbitol [mg]: 6/0.70/210 or 3/0.35/105) in treating subjects with mild to moderate CMT1A.
METHODS
In this study, 323 subjects with mild-to-moderate CMT1A were randomly assigned in a 1:1:1 ratio to receive 5 mL of high- or low-dose PXT3003, or placebo, orally twice daily for up to 15 months. Efficacy was assessed using the change in Overall Neuropathy Limitations Scale total score from baseline to months 12 and 15 (primary endpoint). Secondary endpoints included the 10-m walk test and other assessments. The high-dose group was discontinued early due to unexpected crystal formation in the high-dose formulation, which resulted in an unanticipated high discontinuation rate, overall and especially in the high-dose group. The statistical analysis plan was adapted to account for the large amount of missing data before database lock, and a modified full analysis set was used in the main analyses. Two sensitivity analyses were performed to check the interpretation based on the use of the modified full analysis set.
RESULTS
High-dose PXT3003 demonstrated significant improvement in the Overall Neuropathy Limitations Scale total score vs placebo (mean difference: - 0.37 points; 97.5% CI [- 0.68 to - 0.06]; p = 0.008), and consistent treatment effects were shown in the sensitivity analyses. Both PXT3003 doses were safe and well-tolerated.
CONCLUSION
The high-dose group demonstrated a statistically significant improvement in the primary endpoint and a good safety profile. Overall, high-dose PXT3003 is a promising treatment option for patients with Charcot-Marie-Tooth disease type 1A.
Identifiants
pubmed: 34656144
doi: 10.1186/s13023-021-02040-8
pii: 10.1186/s13023-021-02040-8
pmc: PMC8520617
doi:
Substances chimiques
Sorbitol
506T60A25R
Naltrexone
5S6W795CQM
Baclofen
H789N3FKE8
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
433Informations de copyright
© 2021. The Author(s).
Références
J Biol Chem. 2003 Sep 12;278(37):35159-67
pubmed: 12837761
Eur J Neurol. 2015 Dec;22(12):1556-63
pubmed: 26227902
Curr Neurol Neurosci Rep. 2011 Feb;11(1):78-88
pubmed: 21080241
Cancer Lett. 1996 Mar 29;101(2):159-64
pubmed: 8620464
Neuromuscul Disord. 2006 Jun;16(6):396-402
pubmed: 16684603
J Biol Chem. 2007 Aug 10;282(32):23171-83
pubmed: 17550902
Neuromuscul Disord. 2014 Nov;24(11):1018-23
pubmed: 25092060
Neuromuscul Disord. 2008 Jan;18(1):19-26
pubmed: 17964785
Cochrane Database Syst Rev. 2015 Dec 11;(12):CD011952
pubmed: 26662471
Neuromuscul Disord. 2010 Dec;20(12):839-46
pubmed: 20850975
Neuromolecular Med. 2006;8(1-2):3-22
pubmed: 16775364
Orphanet J Rare Dis. 2014 Dec 18;9:199
pubmed: 25519680
Arch Biochem Biophys. 2009 Nov;491(1-2):1-6
pubmed: 19769937
J Mol Neurosci. 2006;28(1):89-102
pubmed: 16632878
J Neurosci Res. 2006 Jul;84(1):97-105
pubmed: 16634060
J Neurol Neurosurg Psychiatry. 2006 Aug;77(8):973-6
pubmed: 16574730
BMJ. 2003 Jun 28;326(7404):1427
pubmed: 12829555
Ann Biom Biostat. 2013 Jul 5;1(1):
pubmed: 25045756
J Neurol. 2006 Dec;253(12):1572-80
pubmed: 16941080
Orphanet J Rare Dis. 2014 Dec 10;9:201
pubmed: 25491744
Lancet Neurol. 2011 Apr;10(4):320-8
pubmed: 21393063
Neurology. 2008 Jan 29;70(5):378-83
pubmed: 18227419
Planta Med. 1999 Mar;65(2):99-103
pubmed: 10193197
Eur J Neurosci. 2004 May;19(10):2641-9
pubmed: 15147298
Korean J Anesthesiol. 2018 Oct;71(5):353-360
pubmed: 30157585
PLoS One. 2019 Jan 16;14(1):e0209752
pubmed: 30650121
Stat Med. 1992 Sep 30;11(13):1685-704
pubmed: 1485053